It's hard to correlate.
Based on our current minuscule revenues the value of the company is worth little. Doubling or tripling revenue, and the value (or market cap) is still worth little. Certainly well less than the current $20m.
What you are looking for is a history of cumulative growth with revenue, and a product that is scalable - and therefore profitable at a certain point in time.
The value is in the IP and the future potential of the product. So any uplift in sales will definitely impact the share price, but we need to see some velocity in the increase, and some sustainability.
Best way for this to happen is a through a licensing partner, not doubling or tripling of current revenue through OTC sales (even though that will be nice and help the SP).
That was rather long-winded, sorry, but i had a couple of beers at lunch
